RxDoctor Payments Data

Raymond Ha, MD

Internal Medicine · San Francisco, CANPI 1093020638

Payments from drug & device makers

$4,300in general payments, 2019–2025

Across 175 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$748
  • Gilead$702
  • Merck$399
  • Novo Nordisk$384
  • E.r. Squibb & Sons, L.L.C.$307
  • Lilly USA, LLC$289
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,300100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,300 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$41,415
Medicare patients
91
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide28$65,707
JardianceEmpagliflozin27$39,797
FarxigaDapagliflozin Propanediol43$39,769
XareltoRivaroxaban21$35,201
RybelsusSemaglutide12$27,093
EliquisApixaban16$19,739
VascepaIcosapent Ethyl13$7,916
TradjentaLinagliptin11$5,675
Atorvastatin Calcium400$2,747
Losartan Potassium223$2,380
Colchicine15$2,333
Wixela InhubFluticasone Propion/Salmeterol14$2,295
Metformin Hcl202$1,604
Metoprolol Succinate94$1,570
Tamsulosin Hcl74$1,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$702$65,70728 claims
Boehringer IngelheimJardiance, Tradjenta$155$45,47238 claims
AstraZenecaFarxiga$223$39,76943 claims
Johnson & JohnsonXarelto$103$35,20121 claims
Novo NordiskRybelsus$384$27,09312 claims
PfizerEliquis$748$19,73916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →